Departments of Medicine, Pharmacology and Toxicology, Norris Cotton Center and Dartmouth Medical School, Lebanon, NH 03756, USA.
Cancer Gene Ther. 2010 May;17(5):325-33. doi: 10.1038/cgt.2009.75. Epub 2009 Oct 23.
The aim of this study was to assess the biological consequences of cyclin D1 silencing in pancreatic cancer cells. A replication-defective lentivirus based small hairpin RNA (shRNA) system targeting cyclin D1 caused a marked reduction in cyclin D1 protein levels in ASPC-1 and BxPC3 pancreatic cancer cell lines in conjunction with decreased cell growth and invasiveness in vitro. Moreover, a single intratumoral injection of the recombinant lentivirus targeting cyclin D1 attenuated the growth of pre-existing tumors arising from two distinct cell lines. This attenuated growth correlated with decreased proliferation and angiogenesis, as well as attenuated vascular endothelial growth factor expression. It is concluded that lentivirus-delivered shRNA targeting cyclin D1 suppresses the growth, invasiveness, tumorigenicity and pro-angiogenic potential of human pancreatic cancer cells, thereby raising the possibility that intratumoral injections of viruses targeting cyclin D1 could provide a new therapeutic approach in pancreatic ductal adenocarcinoma.
本研究旨在评估细胞周期蛋白 D1 沉默对胰腺癌细胞的生物学影响。针对细胞周期蛋白 D1 的复制缺陷型慢病毒短发夹 RNA(shRNA)系统可使 ASPC-1 和 BxPC3 胰腺癌细胞系中的细胞周期蛋白 D1 蛋白水平显著降低,同时体外细胞生长和侵袭能力下降。此外,单次肿瘤内注射靶向细胞周期蛋白 D1 的重组慢病毒可减弱源自两种不同细胞系的现有肿瘤的生长。这种生长减弱与增殖和血管生成减少以及血管内皮生长因子表达减弱相关。因此,慢病毒介导的 shRNA 靶向细胞周期蛋白 D1 可抑制人胰腺癌细胞的生长、侵袭、致瘤性和促血管生成潜力,从而使靶向细胞周期蛋白 D1 的病毒瘤内注射可能为胰腺导管腺癌提供一种新的治疗方法。